| Idioma original | English |
|---|---|
| Páginas (desde-hasta) | E677-E687 |
| Publicación | CMAJ |
| Volumen | 190 |
| N.º | 22 |
| DOI | |
| Estado | Published - jun. 4 2018 |
Nota bibliográfica
Funding Information:personal fees from AbbVie, Gilead, BristolMyers Squibb, Intercept, Janssen, Merck, Roche and Lupin, and grants from Janssen and Boehringer Ingelheim, outside the submitted work. Marc Bilodeau reports personal fees from AbbVie, Gilead, GSK, Merck, Vertex and Roche, and grants from Merck and GSK, during the conduct of the study, and reports grants from Synageva, Verlyx and BristolMyers Squibb, and personal fees from Verlyx, outside the submitted work. Kelly Burak reports grants from Bayer, Verlyx and Lupin, and personal fees from Merck, Astellas, Bayer, Gilead and Amgen, outside the submitted work. Curtis Cooper reports grants and personal fees from Gilead, Merck and AbbVie, outside the submitted work. Marina Klein reports grants from ViiV Healthcare, Merck and Janssen, and consulting fees from ViiV Healthcare, BristolMyers Squibb, AbbVie and Merck. Alnoor Ramji reports a grant from Gilead; personal fees for clinical trials from AbbVie, Gilead, Janssen, Intercept, Lupin and Merck; and other fees from AbbVie, BristolMyers Squibb, Allergen, Gilead, Janssen, Intercept, Novartis and Merck, outside the submitted work. Dan Smyth reports personal fees from AbbVie, Merck and Gilead, and grants from AbbVie and Gilead, outside the submitted work. Jordan Feld reports grants and personal fees from AbbVie, Merck, Gilead and Janssen; personal fees from Contravir; and grants from Abbott, outside the submitted work. No other competing interests were declared.
ASJC Scopus Subject Areas
- General Medicine
ODS de las Naciones Unidas
Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible
